Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

H.C. Wainwright reiterates Buy rating on Biogen stock at $270

H.C. Wainwright reiterates Buy rating on Biogen stock at $270

H.C. Wainwright has reaffirmed its Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $270.00 following the presentation of Phase 2 CELIA study data for diranersen at CTAD 2026. The stock, currently trading at $251.41, has risen 32% over the past six months and is 4% below its 52-week high. H.C. Wainwright noted that the Week 96 CELIA data demonstrated diranersen's benefits deepening with longer treatment, as the decline in the 60 mg twice-yearly arm slowed significantly, decreasing by 1.09 points on CDR-SB and 42% to 54% on ADAS-Cog-13 compared to the late-start group between Week 76 and Week 96.

Plasma p-tau217 data indicated a roughly half reduction of the marker with no change in amyloid, suggesting potential combination with anti-amyloid approaches. The firm's analysis suggests that the 60 mg twice yearly dose may be optimal for Phase 3 trials, with the lowest rate of confusional state and consistent effects across endpoints.

Biogen's recent strong third-quarter 2026 results, surpassing revenue and earnings expectations, have bolstered investor confidence. This growth is attributed to the company's robust growth portfolio, now accounting for 63% of its pharmaceutical revenues. Other analysts have also raised their price targets for Biogen, with Freedom Broker at $275 and Argus upgrading the stock to Buy. Despite these positive developments, potential headwinds are noted in the fourth quarter of 2026.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →